These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 30477631)

  • 1. [Advances in the treatment of juvenile myelomonocytic leukemia].
    Cai YL; Zhang JL; Zhu XF
    Zhongguo Dang Dai Er Ke Za Zhi; 2018 Nov; 20(11):958-963. PubMed ID: 30477631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia.
    Flotho C; Sommer S; Lübbert M
    Semin Cancer Biol; 2018 Aug; 51():68-79. PubMed ID: 29129488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted therapy in juvenile myelomonocytic leukemia: Where are we now?
    De Vos N; Hofmans M; Lammens T; De Wilde B; Van Roy N; De Moerloose B
    Pediatr Blood Cancer; 2022 Nov; 69(11):e29930. PubMed ID: 36094370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Juvenile myelomonocytic leukemia: who's the driver at the wheel?
    Niemeyer CM; Flotho C
    Blood; 2019 Mar; 133(10):1060-1070. PubMed ID: 30670449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bedside to bench in juvenile myelomonocytic leukemia: insights into leukemogenesis from a rare pediatric leukemia.
    Chang TY; Dvorak CC; Loh ML
    Blood; 2014 Oct; 124(16):2487-97. PubMed ID: 25163700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Juvenile myelomonocytic leukemia.
    Proytcheva M
    Semin Diagn Pathol; 2011 Nov; 28(4):298-303. PubMed ID: 22195407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Juvenile myelomonocytic leukemia.
    Satwani P; Kahn J; Dvorak CC
    Pediatr Clin North Am; 2015 Feb; 62(1):95-106. PubMed ID: 25435114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in the pathogenesis and management of juvenile myelomonocytic leukaemia.
    Koike K; Matsuda K
    Br J Haematol; 2008 May; 141(5):567-75. PubMed ID: 18422786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options.
    Niemeyer CM; Kratz CP
    Br J Haematol; 2008 Mar; 140(6):610-24. PubMed ID: 18302710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The International Consensus Classification (ICC) of hematologic neoplasms with germline predisposition, pediatric myelodysplastic syndrome, and juvenile myelomonocytic leukemia.
    Rudelius M; Weinberg OK; Niemeyer CM; Shimamura A; Calvo KR
    Virchows Arch; 2023 Jan; 482(1):113-130. PubMed ID: 36445482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis and treatment of juvenile myelomonocytic leukemia.
    Sakashita K; Matsuda K; Koike K
    Pediatr Int; 2016 Aug; 58(8):681-90. PubMed ID: 27322988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Childhood myelodysplastic syndrome: focus on the approach to diagnosis and treatment of juvenile myelomonocytic leukemia.
    Loh ML
    Hematology Am Soc Hematol Educ Program; 2010; 2010():357-62. PubMed ID: 21239819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network.
    Caye A; Strullu M; Guidez F; Cassinat B; Gazal S; Fenneteau O; Lainey E; Nouri K; Nakhaei-Rad S; Dvorsky R; Lachenaud J; Pereira S; Vivent J; Verger E; Vidaud D; Galambrun C; Picard C; Petit A; Contet A; Poirée M; Sirvent N; Méchinaud F; Adjaoud D; Paillard C; Nelken B; Reguerre Y; Bertrand Y; Häussinger D; Dalle JH; Ahmadian MR; Baruchel A; Chomienne C; Cavé H
    Nat Genet; 2015 Nov; 47(11):1334-40. PubMed ID: 26457648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Juvenile myelomonocytic leukemia: epidemiology, etiopathogenesis, diagnosis, and management considerations.
    Yoshimi A; Kojima S; Hirano N
    Paediatr Drugs; 2010; 12(1):11-21. PubMed ID: 20034338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Juvenile myelomonocytic leukemias].
    Lachenaud J; Strullu M; Baruchel A; Cavé H
    Bull Cancer; 2014 Mar; 101(3):302-13. PubMed ID: 24691193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induced Pluripotent Stem Cells to Model Juvenile Myelomonocytic Leukemia: New Perspectives for Preclinical Research.
    Wehbe Z; Ghanjati F; Flotho C
    Cells; 2021 Sep; 10(9):. PubMed ID: 34571984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current management of juvenile myelomonocytic leukemia and the impact of RAS mutations.
    Yoshida N; Doisaki S; Kojima S
    Paediatr Drugs; 2012 Jun; 14(3):157-63. PubMed ID: 22480363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia.
    Loh ML
    Br J Haematol; 2011 Mar; 152(6):677-87. PubMed ID: 21623760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment advances for pediatric and adult onset neoplasms with monocytosis.
    McCullough KB; Kuhn AK; Patnaik MM
    Curr Hematol Malig Rep; 2021 Jun; 16(3):256-266. PubMed ID: 33728588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome.
    Olk-Batz C; Poetsch AR; Nöllke P; Claus R; Zucknick M; Sandrock I; Witte T; Strahm B; Hasle H; Zecca M; Stary J; Bergstraesser E; De Moerloose B; Trebo M; van den Heuvel-Eibrink MM; Wojcik D; Locatelli F; Plass C; Niemeyer CM; Flotho C;
    Blood; 2011 May; 117(18):4871-80. PubMed ID: 21406719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.